As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
GLP-1 drug approvals: A breakdown
